Advertisement

How I treat the young patient with multiple myeloma

Sara Gandolfi, Claudia Paba Prada and Paul G. Richardson

Abstract

The treatment landscape for multiple myeloma has been transformed by the introduction of novel agents, including immunomodulatory drugs, proteasome inhibitors, and monoclonal antibodies. These have been shown to be more effective and generally better tolerated than conventional chemotherapy, with their introduction into clinical practice leading to improved survival. Furthermore, a better understanding of disease biology, improved diagnostic criteria, and the development of sensitive and specific tools for disease prognostication have contributed to better outcome. Treatment in the younger patient can now be individualized based on host and disease features with enhanced monitoring of response and use of high-sensitivity techniques for evaluating residual disease. The current standard of care has been significantly enhanced by novel agents with a paradigm shift toward optional or delayed autologous stem cell transplant as a reasonable choice in selected patients. Conversely, extended treatment with induction of remission followed by maintenance strategies is now a standard of care, conferring prolonged disease control with more manageable toxicities in both the short and long term, as well as improved quality of life.

Introduction

Multiple myeloma (MM) is a plasma cell disorder characterized by clonal proliferation of malignant plasma cells in the bone marrow with monoclonal protein in the serum and/or urine and associated organ dysfunction.1,2 Therapeutic advances in MM have evolved at an unprecedented pace in the last 15 years, with more than 22 US Food and Drug Administration (FDA) approvals during this period. The median age at diagnosis is 70 years, with 37% of patients younger than 65 years; MM is rare in those younger than 30 years.2,3 Thus, a considerable proportion of patients are “younger patients,” and the issue of optimal treatment strategies is especially germane, with the goal of improving long-term outcome while minimizing the impact of treatment-related toxicity. MM remains incurable, with a natural history characterized by remission and relapse; although overall survival (OS) has increased dramatically with the advent of novel agents, it is important to consider acute and delayed toxicities, the choice of active agents, and quality of life. Indeed, with the widespread use of novel agents, including proteasome inhibitors (PIs), such as bortezomib, ixazomib, and carfilzomib, and the immunomodulatory drugs (IMIDs) thalidomide, lenalidomide, and pomalidomide, OS has improved from 3 years4 to 7-10 years and beyond.5 The development of monoclonal antibodies has significantly expanded the therapeutic armamentarium, with the depth and duration of remission improving yet further.6

The purpose of this review is to provide a practical approach to the management of newly diagnosed younger MM patients, with a focus on novel treatment approaches. Because there is no established age cutoff to define “young patients,” we will consider as such all patients below the age of 65 years, which is also typically used for transplant eligibility.

When to start treatment: new diagnostic criteria

The definition of active MM relies on clinicopathological criteria that require evidence of end-organ damage attributable to the underlying clonal plasma cell disorder.7,8 However, given the improved tolerability of newer agents, it has become important to identify a subset of patients with smoldering MM (SMM) and an increased chance of progressing to symptomatic disease.

The International Myeloma Working Group (IMWG) revised the disease definition of MM for early diagnosis before end-organ damage occurred.9 The diagnostic criteria update was prompted by the identification of specific biomarkers that accurately distinguished patients with SMM who have ≥80% probability of progression within 2 years and provided the opportunity for early intervention in those patients with highest risk.10 Furthermore, the availability of advanced imaging techniques has allowed detection of bone disease at an earlier stage compared with older techniques, such as skeletal survey.11

The revised diagnostic criteria are listed in Table 1; the diagnosis of MM now requires the presence of ≥1 myeloma-defining event, which include established CRAB features, as well as 3 specific biomarkers: clonal bone marrow plasma cells ≥60%,12-14 serum free light chain (FLC) ratio ≥100 (provided the involved FLC level is ≥100 mg/L),13-16 and ≥1 focal lesion on magnetic resonance imaging (MRI),17,18 provided it is ≥5 mm.9 Each of these biomarkers is associated with an 80% risk for progression to symptomatic end-organ damage in independent studies.

Table 1.

International Myeloma Working Group diagnostic criteria for MM and related disorders

Despite this refinement, SMM still represents a clinical dilemma, and there are no unequivocally validated molecular factors to differentiate patients with higher risk for progression. Further research is required to identify markers of progression in these patients, with ongoing clinical trials investigating early treatment in SMM to evaluate this important area.

When we treat

We treat patients with active MM per 2014 IMWG criteria, and we counsel younger patients with SMM who are eligible for early intervention to consider participation in clinical trials as part of their overall treatment strategy, together with careful observation and the use of bisphosphonates for bone loss.

Risk stratification

Recent advances in molecular biology and genetic studies have improved our understanding of the underlying etiology and progression of MM characterized by diverse intraclonal heterogeneity, which affects disease progression and treatment resistance through clonal evolution.19,20 In addition, the interaction between clonal plasma cells and the bone marrow microenvironment has substantial impact.19,21

Given the heterogeneity of this disease, risk stratification represents a challenge. Several studies have validated multiple biological factors influencing risk and prognosis in MM.22-25

The Durie-Salmon staging system relies on clinical parameters predicting tumor burden.26 The International Staging System (ISS) is a simple tool that includes β2-microglobulin and serum albumin and informs on tumor burden and disease impact on the host.27 The IMWG recently adopted the Revised ISS (R-ISS),28 which combines the ISS and cytogenetic abnormalities detected by interphase fluorescent in situ hybridization (FISH),24 as well as lactate dehydrogenase (LDH),29 to effectively stratify patients with newly diagnosed MM (NDMM) into 3 risk groups (Table 2). In a study of 4445 patients with NDMM from 11 international trials, the 5-year survival rate of patients with stage I, II, or III R-ISS was 82%, 62%, and 40%, respectively,28 with results showing an improvement in OS using novel therapies across prognostic subgroups compared with the original ISS study, in which patients had minimal exposure to more current treatment.

Table 2.

Revised International Staging System for MM

However, the R-ISS study has some limitations, including selection bias, because only younger patients treated in the context of experimental clinical trials were included. Information regarding chromosome abnormalities was not uniform, which limits conclusions to be drawn about their significance, as there was no standardization of FISH analysis, and heterogeneous cutoff levels for LDH were used. Furthermore, the lack of patient-related factors and other features may also influence the prognosis; for example, proliferation index, extramedullary disease, and circulating plasma cells were not included.30

In summary, R-ISS represents a reliable algorithm with improved prognostic power compared with the former ISS. We recommend both the ISS and R-ISS prognostic scores. In addition, host-related factors, such as age, performance status, comorbidities, and frailty, should be considered when choosing treatment strategy.23,24,31,32

Case 1

A 42-year-old woman was found to be anemic on routine laboratory work. She was also noted to have an elevated serum total protein of 11.3 g/dL and globulin of 7.7 g/dL. Her previous chemistry profile had been normal. She reported progressive fatigue and malaise. She was referred in July 2010, and serum protein electrophoresis showed an immunoglobulin G (IgG) λ paraprotein of 5.22 g/dL, with suppression of uninvolved immunoglobulins. Her hemoglobin was 8.3 g/dL, with normal renal function and calcium; her albumin was 3.6 g/dL and β2-microglobulin was 3 mg/L. Skeletal survey revealed osteopenia, but no lytic lesions, and MRI similarly showed no focal lesions but a diffusely abnormal bone marrow signal. Bone marrow biopsy was noteworthy for 80% plasmacytosis, with restriction for λ light chain.

Symptomatic ISS stage I IgGλ myeloma was diagnosed, with a standard risk profile on cytogenetics and FISH. She was enrolled in the IFM/DFCI 2009 clinical trial, a randomized prospective phase 3 study comparing lenalidomide, bortezomib, and dexamethasone (RVD) plus stem cell collection and lenalidomide maintenance (arm A) with RVD followed by an autologous stem cell transplant (ASCT), with RVD consolidation and lenalidomide maintenance (arm B), together with concomitant zoledronic acid. She was randomly assigned to arm B, achieved a partial remission after 2 cycles of RVD and was successfully mobilized after cycle 3, followed by ASCT. Post transplant, very good partial remission (VGPR) was confirmed. She received 2 cycles of RVD consolidation and then lenalidomide as maintenance. After 3 months of maintenance, the patient achieved complete remission (CR). She is currently in her 74th month of continuous lenalidomide treatment, in sustained CR, and has some fatigue and occasional recurrent infections but is otherwise well.

Case 2

A 61-year-old man was referred with a diagnosis of IgGκ gammopathy. He was fatigued but denied other symptoms. Significant anemia was noted, with a hemoglobin of 7.6 g/dL. Renal function and calcium were normal. β2-microglobulin (2.6 mg/L) and albumin (3.3 g/dL) were consistent with ISS stage II disease. Quantitative immunoglobulins were noteworthy for an IgG of 2870 mg/dL, with suppression of uninvolved immunoglobulins, and κ light chains were elevated at 73.7 mg/L with a ratio of 24.2. Skeletal survey showed osteopenia and lytic disease in the spine. Bone marrow biopsy was noteworthy for 60% plasmacytosis, with flow cytometry demonstrating κ light chain–restricted plasma cells. Cytogenetics revealed a normal male karyotype with 46, XY, and FISH analysis was negative.

He was enrolled in the same trial and was randomized to the delayed transplant arm (arm A). He achieved VGPR after 2 cycles of induction with RVD and concurrent zoledronic acid and entered CR after mobilization with high-dose cyclophosphamide and granulocyte-colony stimulating factor. He completed 8 cycles of RVD and tolerated treatment well. He is in a sustained CR at month 64 of continuous lenalidomide maintenance and is asymptomatic.

Choice of initial treatment in the era of novel agents

The incorporation of novel agents in MM treatment has resulted in a major improvement in OS,33 with induction regimens containing ≥3 drugs, including PIs and IMIDs, appearing to be the best choice for initial therapy (Figure 1).5,34 The combination of these 2 classes of drugs has shown synergy in preclinical models and clinically, yielding increased response and improved outcome.34-41 Data from phase I/II trials were recently confirmed in a phase III SWOG study, in which RVD was compared with lenalidomide and dexamethasone alone in NDMM and in a landmark study of RVD with or without early ASCT and lenalidomide maintenance.42,43 The latter study showed a CR + VGPR rate of 77% and minimal residual disease (MRD) negativity rate of 65%, with a progression-free survival (PFS) of 36 months, in the RVD arm without early ASCT whereas median OS was not reached. These outstanding results, along with ≥63% CR reported with the second-generation PI carfilzomib, in combination with lenalidomide and dexamethasone (KRD),38 strongly support the use of triplets in NDMM patients. Ixazomib combined with lenalidomide and dexamethasone has shown remarkable overall response rate in 2 single-arm phase II studies in younger transplant-eligible and older patients, with excellent PFS and OS, favorable tolerability, and the added convenience of an all-oral combination.39,44 Importantly, data from randomized trials using combinations of PIs and IMIDs also show favorable tolerability, with results from the SWOG trial well balanced for adverse events between the 2 groups.42 Another combination to be considered is cyclophosphamide, bortezomib and dexamethasone (CyBorD), which is highly active in NDMM, although a recent randomized trial found that the triplet regimen containing a PI and an IMID is superior to CyBorD.45 However, this regimen is particularly useful and part of our practice in patients with acute renal failure suspected to be secondary to light-chain cast nephropathy. Similarly, in patients with underlying neuropathy, we favor KRD, given its minimal neurotoxicity and remarkable efficacy. In younger patients, in whom the risk for vascular toxicity and cardiac complications may be lower, this regimen may be especially valuable.

Figure 1.

Proposed guidelines for management of younger MM patients. CyBorD, cyclophosphamide, bortezomib, dexamethasone; ISS, International Staging System; KRD, carfilzomib, lenalidomide, dexamethasone; PN, peripheral neuropathy; R-ISS, revised International Staging System; RVD, lenalidomide, bortezomib, dexamethasone; IRD, ixazomib, lenalidomide, dexamethasone.

Our practice

Patients not eligible or choosing not to be included in a clinical trial are treated with RVD for 6-8 cycles as initial treatment or other combinations (eg, KRD, ixazomib/lenalidomide/dexamethasone, or CyBorD), followed by stem cell collection; ASCT is also considered, with maintenance to follow (Figure 1).

Role of stem cell transplant

High-dose chemotherapy followed by ASCT is still considered a standard of care in eligible patients based on a series of randomized trials demonstrating improved PFS and OS.46-52 Two more recent phase III clinical trials showed a significant PFS benefit and an OS advantage, but induction included doublets or combinations without PIs.53,54 The depth and duration of response achieved with the triplet combination of IMID, PI, and dexamethasone and its favorable tolerability is now challenging this paradigm. Given the acute and long-term toxicities of ASCT, including the rare, but life-threatening complication of secondary leukemia, the role of ASCT as part of upfront treatment is an area of active research.43,53-55 Interestingly, as described above, the French part of the IFM/DFCI 2009 trial has demonstrated a clear PFS advantage but no OS benefit.43 Competing causes of mortality included acute toxicities of ASCT, as well as rare cases of secondary leukemia, although the follow-up remains short to establish actual rates of long-term toxicity.43,56 Of note, the IFM study completes lenalidomide maintenance after 1 year, whereas in the ongoing US study, lenalidomide is continued until progression.

The European Myeloma Network/Stichting Hemato-Oncologie voor Volwassenen Nederland (HOVON) recently reported the EMN02/HO95 results.55 In this phase III trial, patients were treated with CyBorD induction and then randomized to receive ASCT (single or tandem) or bortezomib, melphalan, and prednisone. A second randomization to consolidation therapy vs no consolidation was performed after intensification therapy using RVD, followed by lenalidomide maintenance until progression in both arms. The 3-year estimates of PFS favor the ASCT arm, but again no difference in OS was observed.55

None of the above studies addressed the role of ASCT at time of first relapse.43,53-55 In the trial presented by Palumbo et al, 70% of patients received ASCT as second-line therapy after relapse, whereas Gay et al reported that 43% of patients in the cyclophosphamide-lenalidomide-dexamethasone arm underwent ASCT.53,54 A pooled analysis of these 2 trials showed that patients receiving conventional chemotherapy, with ASCT as intensification and lenalidomide maintenance after first relapse, had an improvement in OS.57 However, some caution is warranted with this interpretation, because PFS2 was not a prespecified end point in the original studies, and postrelapse treatment was not homogeneous, with only 10% of patients receiving post-ASCT maintenance.

One randomized trial including ASCT as a preplanned option at first relapse was published, prior to the advent of novel agents. No differences in OS were reported, despite a significant advantage in terms of PFS with upfront ASCT.47 Given the impact of novel agents and other immunotherapeutic strategies on MM outcome, research on the role and timing of ASCT, as well as identification of those subsets of patients in whom the benefit of ASCT outweighs the risk of toxicities, is critical. Participation in prospective trials is encouraged as the treatment paradigm continues to evolve and important unanswered questions remain.5 Specifically, a key issue is the identification of patient- and disease-specific markers, with the goal of exposing only those who benefit from early ASCT to the procedure.

Our practice

Although ASCT remains a standard of care in MM, this paradigm has evolved with the advent of newer and less toxic therapies, such that a rigid approach to ASCT upfront use outside of clinical studies is difficult to justify.58 We recommend participation in clinical trials, but for those who are ineligible or decide not to participate, ASCT as an option remains appropriate (Figure 1). For patients preferring to delay ASCT after induction/remission therapy, they should be encouraged to harvest stem cells as soon as a sustained best response is reached (eg, VGPR or better).

Tandem stem cell transplant

The use of planned sequential ASCT has been investigated in several randomized clinical trials,22,59,60 and meta-analyses have shown superior response rates with tandem ASCT but no difference in OS. However, heterogeneity limits this analysis.61,62 Recently, the German-Speaking Myeloma Multicenter Group presented long-term follow-up of the HD2 study, which reported no differences in EFS or OS between single and tandem ASCT. Furthermore, preliminary data from the BMT CTN 0702 trial, which randomized patients to receive single ASCT with lenalidomide maintenance vs single ASCT with RVD consolidation and lenalidomide maintenance vs tandem ASCT with lenalidomide maintenance, demonstrated comparable PFS and OS across all 3 treatment arms.63 Given these results and the concerns of cumulative long-term marrow toxicity from double high-dose alkylation, we do not recommend routine tandem ASCT outside of a clinical trial.

Allogeneic transplant

Myeloablative allogeneic stem cell transplant (allo-SCT) is associated with a transplant-related mortality rate of 40-60%, which has proven prohibitive to the widespread use of this modality in younger patients. As a result, reduced-intensity approaches have been recently investigated.64 Given that the results of several trials comparing ASCT and allo-SCT in the upfront setting have failed to show any consistent benefit to allo-SCT, and nonrelapse mortality rate has been significantly higher with allo-SCT, it is not recommended as a first-line approach. A reduced-intensity approach allo-SCT can be considered in the salvage setting for younger patients with good performance status and high-risk cytogenetic features, preferably in the context of a clinical trial.

Consolidation

Consolidation following ASCT consists of a short course of multiagent therapy aiming at improving the depth of the response with the goal of prolonging clinical benefit. Four randomized trials have evaluated different post-ASCT approaches, and all have shown an improvement in depth of responses but did not provide OS benefit.36,65-68 A prespecified analysis of a phase III study presented by Gruppo Italiano Malattie EMatologiche dell'Adulto showed that bortezomib-thalidomide-dexamethasone (VTD) as a consolidation therapy improved PFS, but there was no benefit in terms of OS.65 A trial conducted by the Nordic Myeloma Study Group compared consolidation with bortezomib after ASCT with no consolidation; the study showed an improvement in response after randomization and significant PFS advantage, but there was no OS benefit.66 The German group presented a prespecified analysis on combined data from 2 randomized phase III studies of bortezomib consolidation, which confirmed its role in delaying disease progression and improving the quality of responses in NDMM patients following ASCT.67 Results from the EMN02/HO95 trial55 also confirmed a PFS advantage in patients receiving consolidation. However, a PFS advantage was observed only in patients with low-risk cytogenetics.68 Preliminary results from the BMT-CTN 0702 trial suggested that the addition of RVD consolidation or a second ASCT was not superior to a single ASCT followed by lenalidomide maintenance in the upfront treatment of MM with regard to PFS and OS, although a trend toward PFS benefit was seen in the RVD-treated population and high-risk disease.63 Follow-up is ongoing and should better help to understand the impact of these results, with all 3 groups achieving excellent outcomes to date, including high-risk disease.

Our practice

Considering that data from the BMT-CTN 0702 trial are still preliminary and that trials have shown a PFS benefit with consolidation treatment, we offer 2-4 cycles of RVD after ASCT in high-risk patients and for those who do not achieve CR after transplant (Figure 1).

Maintenance and continuous therapy

Despite the improvement in PFS and OS with novel approaches and ASCT, relapses are inevitable for the majority of patients, primarily due to incomplete eradication of residual disease. Maintenance is a treatment strategy aimed at prolonging and deepening the response to previous induction, with or without ASCT. As defined, maintenance must be a long-term treatment, typically considered therapy administered for ≥1 year.69

Although first attempts at maintenance therapy using conventional chemotherapy, steroids, or interferon-α proved disappointing,70-75 the advent of novel agents has markedly restored its potential to improve clinical benefit.

Several clinical trials have investigated the role of thalidomide as post-ASCT maintenance.76-85 These studies were heterogeneous in terms of dosing and schedule, with varied results in terms of outcome.69,82,86 Thalidomide presents significant dose-limiting toxicity, including peripheral neuropathy and an increased risk for venous thromboembolism, as well as cognitive dysfunction, fatigue, and constipation. Given the better tolerability of lenalidomide, the use of post-ASCT thalidomide is now generally limited to those patients who cannot tolerate the myelosuppressive effects of lenalidomide or other agents.

Three large randomized clinical trials have investigated the role of lenalidomide in the post-ASCT setting.53,87-89 All of these studies have demonstrated a PFS improvement by ∼2.5 years using lenalidomide maintenance, particularly until progression, with varying effects on OS. A recent meta-analysis involving 1209 patients showed significant OS benefit, regardless of the response achieved post-ASCT.90 Considering these data, the benefits of lenalidomide maintenance after ASCT outweigh the small risk for increased secondary malignancies reported in 2 out of 3 trials,87,89 and support lenalidomide maintenance post-ASCT being a standard of care.

There are no placebo-control randomized trials investigating bortezomib as maintenance strategy. Two randomized trials have addressed the issue of post-ASCT bortezomib maintenance.41,91 The phase III HOVON-65/German-Speaking Myeloma Multicenter Group–HD4 trial showed that bortezomib maintenance after bortezomib-containing induction improved the CR rate and was better tolerated than thalidomide. This trial also demonstrated an improvement in PFS and OS, particularly in patients with del17p.92 Data from the Spanish group showed a PFS advantage in patients treated with post-ASCT bortezomib-thalidomide maintenance compared with thalidomide or α-interferon for up to 3 years, but with no OS advantage. In aggregate, these data suggest a role for bortezomib maintenance in the posttransplant setting, especially for those patients carrying high-risk cytogenetics, such as del(17p). Similar benefit in high-risk patients is also apparent with the long-term use of ixazomib as continuous therapy.

Our practice

Post-ASCT, lenalidomide maintenance is a standard of care and is offered to all patients undergoing ASCT, with dose adjustments and schedule change according to tolerability. High-risk patients, especially those carrying 17p deletion, are offered the addition of bortezomib.93 Patients who are not willing to participate in clinical trials and who chose to delay ASCT, are offered continuous therapy with both lenalidomide and bortezomib (Figure 1). Ideally, maintenance should be administered until disease progression; however, this approach is not always feasible, and dose adjustment as well as schedule changes and discontinuation may be necessary if toxicity emerges.

Immunotherapy and monoclonal antibodies

Immune function in MM has recently generated great interest and is an active area of research, with the recent evaluation of checkpoint inhibition in combination with IMIDs, as well as monoclonal antibodies, each of which have shown outstanding activity in advanced disease.56,94 Impressive quality and durability of response are being seen with CD38-targeting antibodies used in combination and as monotherapy, as well as with anti-SLAMF7 antibody elotuzumab.95-98 Although elotuzumab as a single agent showed disappointing results, its combination with lenalidomide and bortezomib demonstrated high response rate and improvement in PFS in relapsed and refractory disease, with a manageable toxicity profile.99-102 Conversely, daratumumab demonstrated powerful activity both as a single agent and in combination, with unprecedented efficacy in relapsed/refractory MM.103 Two separate phase II studies with daratumumab as a single agent in heavily pretreated patients resulted in a partial response or better in nearly one third of patients. The responses were durable, with the median response exceeding a year, leading to FDA approval.96,104,105 Two large phase III trials recently reported a remarkable improvement in PFS with the addition of daratumumab to an IMID or PI.106,107 Daratumumab is generally well tolerated, with the main adverse event being infusion reactions. Both agents are being evaluated in transplant-eligible and transplant-ineligible NDMM patients, with recent results suggesting substantial clinical benefit. These trials will help to address the issue of the integration of such agents in clinical practice, as well as drug sequencing. Another intriguing aspect is their potential role in early vs delayed transplant strategies.

The promising results obtained with therapeutic checkpoint inhibition in multiple cancers has opened the possibility of its application in MM. Despite strong in vitro and in vivo evidence of PD-1/PD-L1 having a role in this disease, results from single-agent nivolumab proved disappointing.103,108 In contrast, combinations of checkpoint inhibitors with IMIDs have demonstrated improved clinical activity, even in patients with double-refractory disease.109 However, 2 phase III trials evaluating the combination of lenalidomide (NCT02579863) and pomalidomide (NCT02576977) with pembrolizumab in patients with newly diagnosed and relapsed MM, respectively, were closed due to toxicity and inferior survival compared with control upon early analysis. Combinations of checkpoint inhibitors with daratumumab and elotuzumab were also initiated, but the unexpected serious toxicity seen with pembrolizumab led to clinical holds by the FDA with these studies as well (NCT01592370, NCT02252263, NCT02726581). Multiple other targets are now under study, including B-cell maturation antigen. Other exciting strategies include vaccines,110,111 and especially chimeric antigen receptor–T-cell therapy, which may be paradigm changing for younger patients eligible for this approach.112,113

Response assessment and the role of MRD

Response criteria in MM rely on serum and urine measurement of monoclonal proteins and bone marrow assessment, but a serological/morphological CR may still underestimate residual disease. Recently, the IMWG has incorporated multicolor immunofluorescence flow cytometry and gene sequencing with sensitivity of up to 10−5 into MM response criteria, as well as the absence of bone disease on positron emission tomography/computed tomography scanning.114 Two meta-analyses confirmed that MRD-negative status after treatment of NDMM is associated with significant improvement in survival and support the integration of MRD assessment in clinical trials.115,116 However, the IFM/DFCI trial shows that ∼25% of MRD-negative patients still experience relapse at 36 months, despite better PFS and OS curves compared with MRD-positive patients (Figure 2).43 These data indicate that more sensitive tools are required to detect MRD and question whether current MRD technologies alone are enough to inform patients about prognosis. Newer approaches for measuring MRD, such as single-cell gene sequencing and serum cell-free DNA, may more accurately assess MRD and complement existing methods. Additional data are needed to establish MRD for registration of new agents and to inform clinical practice.117 Considering the wide array of generally well-tolerated drugs, a reasonable strategy would be to tailor treatment to patient response. In this context, dynamic risk-assessment tools and reliable markers predictive of outcome are warranted, and clinical trials will be pivotal in evaluating these prognostic modalities.

Figure 2.

Kaplan-Meier curves for PFS (A) and OS (B), according to MRD, in the IFM trial. Despite PFS and OS being prolonged in MRD-negative patients vs those who were MRD positive (adjusted hazard ratio [aHR], 0.30; 95% confidence interval [CI], 0.23-0.37; P < .001 and aHR, 0.34; 95% CI, 0.22-0.51; P < .001 respectively), progression occurred in ∼25% of MRD-negative patients at a median of 36 months follow-up, which, in turn, impaired OS.43

Supportive care

General supportive measures include adequate hydration, low-impact exercise, weight control,118 avoidance of nephrotoxic drugs, prevention of neuropathy, and pain management. Attention regarding infection is critical, and antiviral prophylaxis is recommended in patients receiving PIs to minimize the development of herpes zoster reactivation.119,120

Thromboprophylaxis is indicated when IMIDs are used. Patients at low risk for thrombosis and receiving IMIDs with daily aspirin (81 or 325 mg) show a low rate of deep vein thrombosis, but this still can affect up to ∼5-10% of patients. For patients at higher risk for deep vein thrombosis resulting from other factors, such as prior history, immobility, obesity, cardiovascular disease, and smoking, therapeutic anticoagulation using low molecular weight heparin or warfarin is recommended.121 Factor Xa inhibitors (direct oral anticoagulants, so-called DOACs) are currently under study in this setting, but appear to be a feasible new approach.

The use of intravenous bisphosphonates, such as zoledronic acid and pamidronate, is recommended, regardless of whether bone lesions have been detected. These interventions have been associated with a reduction in skeletal events and may also have direct antitumor activity.122 Despite a recent phase II trial comparing the standard-of-care 24-month bisphosphonate treatment with a 4-year treatment not showing OS benefit, a clear reduction in skeletal events was demonstrated.123 Overall, the benefits of bisphosphonate therapy should be weighed with their toxicities, and preventive strategies must be instituted to avoid renal toxicity or osteonecrosis of the jaw.25 The RANKL inhibitor denosumab is a promising agent, especially in patients with renal impairment. A post hoc analysis of a phase III clinical trial was not conclusive due to imbalances in the baseline and on-study variables and unequal early withdrawal with censoring in the MM subset. An adequately sized confirmatory phase 3 trial of denosumab and zoledronic acid in MM patients is now complete with positive results reported (NCT01345019).124

Other measures include evaluation and management of neuropathy, cytopenias, and diarrhea common to PI and IMID use, with neuropathy an area of particular importance.125

Practical considerations

In countries with more limited resources and in which multiple novel agents have not yet been approved for upfront treatment, we suggest the use of best-available induction regimens, favoring triplets such as a PI and/or an IMID with steroids and chemotherapy. Ideally, regimens should include both, such as bortezomib, thalidomide, and dexamethasone (VTD) or cyclophosphamide, thalidomide, bortezomib, and dexamethasone, or CyBorD for 4-6 cycles, followed by ASCT, especially if maintenance strategies are not yet approved. Nevertheless, if after the first initial 3 or 4 cycles the patient has achieved less than a partial response, the use of salvage therapy based on available drugs (eg, RVD, KRD, or regimens including monoclonal antibodies) before transplantation is recommended, as well as consideration of inclusion of other chemotherapeutics, such as anthracyclines. Finally, maintenance with best-available strategies, such as bisphosphonate, thalidomide, and /or bortezomib, should also be considered, with other novel agents held in reserve for relapse, according to respective approvals and availability.

Conclusions and future directions

In conclusion, we recommend that, in younger patients with NDMM, active treatment should be initiated as early as possible, and broadly in accordance with IMWG criteria. Induction treatment should contain an IMID, PI, and steroids, because triplets are associated with increased depth and quality of response as well as clinical benefit. Given the rapidly changing treatment paradigm and the efficacy of novel agent combinations, ASCT can reasonably be kept in reserve for patients who do not wish to initially pursue high-dose therapy, with postinduction continuous therapy using lenalidomide recommended and PIs added as clinically appropriate. In patients undergoing ASCT, consolidation therapy after ASCT is favored, followed by maintenance with lenalidomide. The addition of bortezomib to maintenance therapy should be considered in patients with high-risk cytogenetics, with other PIs also considered as clinically indicated. Typically, the prognostic risk profile of a patient should be determined using clinical and genetic features. In all patients, careful attention to supportive care plays a critical role, not least because it allows the avoidance of early complications that may compromise subsequent therapeutic outcome.25,118-124 Several other factors should be considered while planning treatment strategy, such as logistics, out-of-pocket cost, drug availability, social considerations, comorbidities, and patient preference. The current wide availability of options allows a tailored approach, with improved efficacy. New directions include monoclonal antibodies, vaccines, cellular therapy, and small molecules, such as histone deacetylase inhibitors and other targeted therapies, as well as bone-targeting agents, including denosumab.124,126 Participation in large phase III trials investigating the best approach in newly diagnosed younger patients is strongly recommended and should be considered for all eligible patients.

Acknowledgments

The authors gratefully acknowledge the editorial assistance of Michelle Maglio, Rashana Lord, and Jack Sparacino in the preparation of this manuscript.

This work was supported in part by the R.J. Corman Multiple Myeloma Research Fund.

Authorship

Contribution: S.G. developed the first draft and edited and wrote the manuscript, and C.P.P. and P.G.R. edited and wrote the manuscript.

Conflict-of-interest disclosure: P.G.R. is a member of advisory committees for Celgene, Takeda, Janssen, Oncopeptides, and Amgem and has received research funding from BMS, Takeda, and Celgene. The remaining authors declare no competing financial interests.

Correspondence: Paul G. Richardson, Dana-Farber Cancer Institute, 450 Brookline Ave, Mayer 228, Boston, MA 02215; e-mail: paul_richardson{at}dfci.harvard.edu.

  • Submitted May 5, 2017.
  • Accepted June 1, 2018.

REFERENCES

  1. 1.
  2. 2.
  3. 3.
  4. 4.
  5. 5.
  6. 6.
  7. 7.
  8. 8.
  9. 9.
  10. 10.
  11. 11.
  12. 12.
  13. 13.
  14. 14.
  15. 15.
  16. 16.
  17. 17.
  18. 18.
  19. 19.
  20. 20.
  21. 21.
  22. 22.
  23. 23.
  24. 24.
  25. 25.
  26. 26.
  27. 27.
  28. 28.
  29. 29.
  30. 30.
  31. 31.
  32. 32.
  33. 33.
  34. 34.
  35. 35.
  36. 36.
  37. 37.
  38. 38.
  39. 39.
  40. 40.
  41. 41.
  42. 42.
  43. 43.
  44. 44.
  45. 45.
  46. 46.
  47. 47.
  48. 48.
  49. 49.
  50. 50.
  51. 51.
  52. 52.
  53. 53.
  54. 54.
  55. 55.
  56. 56.
  57. 57.
  58. 58.
  59. 59.
  60. 60.
  61. 61.
  62. 62.
  63. 63.
  64. 64.
  65. 65.
  66. 66.
  67. 67.
  68. 68.
  69. 69.
  70. 70.
  71. 71.
  72. 72.
  73. 73.
  74. 74.
  75. 75.
  76. 76.
  77. 77.
  78. 78.
  79. 79.
  80. 80.
  81. 81.
  82. 82.
  83. 83.
  84. 84.
  85. 85.
  86. 86.
  87. 87.
  88. 88.
  89. 89.
  90. 90.
  91. 91.
  92. 92.
  93. 93.
  94. 94.
  95. 95.
  96. 96.
  97. 97.
  98. 98.
  99. 99.
  100. 100.
  101. 101.
  102. 102.
  103. 103.
  104. 104.
  105. 105.
  106. 106.
  107. 107.
  108. 108.
  109. 109.
  110. 110.
  111. 111.
  112. 112.
  113. 113.
  114. 114.
  115. 115.
  116. 116.
  117. 117.
  118. 118.
  119. 119.
  120. 120.
  121. 121.
  122. 122.
  123. 123.
  124. 124.
  125. 125.
  126. 126.
View Abstract